Red Book

Early detection of cancers

Testicular cancer

Guidelines for preventive activities in general practice
Download PDF
  2. Figures and tables
  3. Provided under licence
  4. Search

Age range chart
0-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-79 >80

Not recommended as a preventive activity


There is insufficient evidence to routinely screen for testicular cancer using clinical or self-examination.105,106 Those performing testicular self-examination are not more likely to detect early-stage tumours or have better survival than those who do not (C).

Testicular cancer: Identifying risk

Table 9.7.1

Testicular cancer: Identifying risk
Download View full size

  1. Cancer Council Australia. Community Care and Population Health Principal Committee of the Australian Health Ministers’ Advisory Council ; NHMRC summary of the evidence. Sydney: Cancer Council Australia, 2014.
  2. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ 2010;341:c4543.
  3. National Health and Medical Research Council. PSA testing for prostate cancer in asymptomatic men. Information for health practitioners. Canberra: NHMRC, 2014.
  4. Lim LS, Sherin K, ACPM Prevention Practice Committee. Screening for prostate cancer in US men: ACPM position statement on preventive practice. Am J Prev Med 2008;34(2):164–70.
  5. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003;107(5):797–803.
  6. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91(9):789–94.
  7. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-analysis. Cancer 2003;97(8):1894–903.
  8. Ilic D, O’Connor D, Green S, Wilt TJ. Screening for prostate cancer: An updated Cochrane systematic review. BJU Int 2011;107(6):882–91.
  9. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720.
  10. Moyer on behalf of US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;157(2):120–34.
  11. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306(11):1204–14.
  12. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250–61.
  13. Fang F, Keating NL, Mucci LA, et al. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: Cohort study in the United States. J Natl Cancer Inst 2010;102(5):307–14.
  14. Fall K, Fang F, Mucci LA, et al. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: Prospective cohort study. PLoS Med 2009;6(12):e1000197.
  15. Bowden FJ, Roberts J, Collignon PJ. Prostate cancer screening and bacteraemia (letter). Med J Aust 2008;188(1):60.
  16. Gattellari M, Ward J. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screening 2003;10:27–29.
  17. Hewitson P, Glasziou PP, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;1:CD001216.
  18. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J. Evaluating test strategies for colorectal cancer screening-age to begin, age to stop, and timing of screening intervals: A decision analysis of colorectal cancer screening for the US Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling Network (CISNET). Rockville, MD: Agency for Healthcare Research and Quality, 2009.
  19. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee. Guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia and Australian Cancer Network, 2005.
  20. Viiala CH, Zimmerman M, Cullen DJ, Hoffman NE. Complication rates of colonoscopy in an Australian teaching hospital environment. Intern Med J 2003;33(8):355–59.
  21. Rabeneck L, Paszat LF, Hilsden RJl. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135(6):1899–906, 906 e1.
  22. US Preventive Services Task Force. Draft Recommendation Statement – Colorectal Cancer: Screening. 2015 draft-recommendation-statement38/colorectal-cancerscreening2#citation10 [Accessed 15 October 2015].
  23. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol Assess 2010;14(32):1–206. [Accessed 15 October 2015].
  24. National Cancer Institute. Colorectal cancer screening (PDQ®) – Health Professional Version. US National Institutes of Health, 2012 HealthProfessional/page4 [Accessed 2015 October].
  25. Australian Cancer Network. Familial aspects of bowel cancer: A guide for health professionals. Canberra: National Health and Medical Research Council, 2002. [Accessed 2015 October].
  26. National Cancer Institute. Genetics of colorectal cancer (PDQ®) – Health Professional Version. US National Institutes of Health, 2012 cancertopics/pdq/genetics/colorectal/HealthProfessional/ page1 [Accessed 15 October 2015].
  27. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet 2011;378(9809):2081–87. [Accessed 15 October 2015].
  28. Rothwell PM, Fowkes PG, Belch JP, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long term risk of death due to cancer – Analysis of individual patient data from randomised trials. Lancet 2011;377(9759):31–41. [Accessed 15 October 2015].
  29. Rothwell PM, Wilson M, Elwin CE, et al. Long term effect of aspirin on colorectal cancer incidence and mortality: 20 year follow up of 5 randomized controlled trials. Lancet 2010;376(9754):1741–50. [Accessed 15 October 2015].
  30. Cancer Council Australia Colonoscopy Surveillance Working Party. Clinical practice guidelines for surveillance colonoscopy – In adenoma follow-up; following curative resection of colorectal cancer; and for cancer surveillance in inflammatory bowel disease. Sydney: Cancer Council Australia, 2011. [Accessed 15 October 2015].
  31. van Dam L, Kuipers EJ, van Leerdama ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010;24(4):479–92. [Accessed 15 October 2015].
  32. Holden DJ, Jonas DE, Porterfield DS, Reuland D, Harris R. Systematic review: Enhancing the use and quality of colorectal cancer screening. Ann Intern Med 2010;152(10):668–76. [Accessed 15 October 2015].
  33. Steinwachs D, Allen JD, Barlow WE, et al. National Institutes of Health state-of-the-science conference statement: Enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010;152(10):663–67. [Accessed 15 October 2015].
  34. Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, St John DJB. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust 2011;194(4):180–85. [Accessed 15 October 2015].
  35. Zapka J, Taplin SH, Anhang Price R, Cranos C, Yabroff R. Factors in quality care – The case of follow-up to abnormal cancer screening tests – Problems in the steps and interfaces of care. J Natl Cancer Inst Monogr 2010;2010(40):58–71. [Accessed 15 October 2015].
  36. Senore C, Malila N, Minozzi S, Armarolia P. How to enhance physician and public acceptance and utilisation of colon cancer screening recommendations. Best Pract Res Clin Gastroenterol 2010;24(4):509–20. [Accessed 15 October 2015].
  37. Department of Health and Ageing. National Bowel Cancer Screening Program: About bowel screening. Canberra: DoHA, 2012 [Accessed 15 October 2015].
  38. Weber MF, Banks E, Smith DP, O’Connell D, Sitas F. Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study. BMC Public Health 2009;9:144. doi: 10.1186/1471-2458-9-144. [Accessed 15 October 2015].
  39. Evans DG, Warwick J, Astley SM, et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: A new paradigm for cancer prevention. Cancer Prev Res (Phila) 2012;5(7):943–51. [Accessed 15 October 2015].
  40. Hopper JL. Disease-specific prospective family study cohorts enriched for familial risk. Epidemiol Perspect Innov 2011;8(1):2. [Accessed 15 October 2015].
  41. Goncalves AK, Dantas Florencio GL, Maisonnette de Atayde Silva MJ, Cobucci RN, Giraldo PC, Cote NM. Effects of physical activity on breast cancer prevention: A systematic review. J Phys Act Health 2014;11(2):445–54. [Accessed 15 October 2015].
  42. Chen P, Li C, Li X, Li J, Chu R, Wang H. Higher dietary folate intake reduces the breast cancer risk: A systematic review and meta-analysis. Br J Cancer 2014;110(9):2327–38. [Accessed 15 October 2015].
  43. Albuquerque RC, Baltar VT, Marchioni DM. Breast cancer and dietary patterns: A systematic review. Nutr Rev 2014;72(1):1–17. [Accessed 15 October 2015].
  44. Jayasekara H, MacInnis RJ, Room R, English DR. Long-term alcohol consumption and breast, upper aero-digestive tract and colorectal cancer risk: A systematic review and meta-analysis. Alcohol Alcohol 2016;51(3):315–30. [Accessed 15 October 2015].
  45. Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: A consensus statement. Lancet Oncol 2011;12(5):496–503. [Accessed 15 October 2015].
  46. Nelson HD, Pappas M, Zakher B, Mitchell JP, OkinakaHu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: A systematic review to update the US Preventive Services Task Force recommendation. Ann Intern Med 2014;160(4):255–66. [Accessed 15 October 2015].
  47. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45(7):425–31. [Accessed 15 October 2015].
  48. US Preventive Services Task Force. Breast cancer: Screening. Rockville, MD: USPSTF, 2015 Document/UpdateSummaryFinal/breast-cancerscreening1?ds=1&s=breast%20cancer [Accessed 15 November 2015].
  49. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013;108(11):2205–40. [Accessed 15 November 2015].
  50. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311(13):1327–35. [Accessed 15 November 2015].
  51. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;6:Cd001877. [Accessed 15 November 2015].
  52. Walter LC, Schonberg MA. Screening mammography in older women: A review. JAMA 2014;311(13):1336–47. [Accessed 15 November 2015].
  53. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breastcancer screening – Viewpoint of the IARC Working Group. N Engl J Med 2015;372(24):2353–58. [Accessed 15 November 2015].
  54. Cancer Australia. MRI for high risk women. Sydney: Cancer Australia, 2015. Available at https:// [Accessed 15 November 2015].
  55. Cancer Australia. Advice about familial aspects of breast and epithelial ovarian cancer: A guide for health professionals. Sydney: Cancer Australia, 2015 publications/advice-about-familial-aspects-breastcancer-and-epithelial-ovarian-cancer/pdf/2015_bog_ familial_aspects_int.pdf [Accessed 15 November 2015].
  56. Pruthi S, Heisey RE, Bevers TB. Chemoprevention for breast cancer. Ann Surg Oncol 2015;22(10):3230–35. [Accessed 15 November 2015].
  57. Bonfill X, Marzo M, Pladevall M, Marti J, Emparanza JI. Strategies for increasing the participation of women in community breast cancer screening. Cochrane Database Syst Rev 2001;1:CD002943. [Accessed 15 November 2015].
  58. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet 1999;354(9180):723–29. [Accessed 15 November 2015].
  59. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: Randomised trial follow-up. J Clin Oncol 2011;29(3):257–63. [Accessed 15 November 2015].
  60. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical practice guidelines of the management of melanoma in Australian and New Zealand. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008. [Accessed 15 November 2015].
  61. Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open 2015;5(9):e008158. [Accessed 15 November 2015].
  62. Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012;118(21):5395–402. [Accessed 15 November 2015].
  63. Usher-Smith JA, Emery J, Kassianos AP, Walter FM. Risk prediction models for melanoma: A systematic review. Cancer Epidemiol Biomarkers Prev 2014;23(8):1450–63. [Accessed 15 November 2015].
  64. Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: A systematic review. Br J Dermatol 2015;172(1):33–47. [Accessed 15 November 2015].
  65. MacKie R, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993;341(8861):1618–20. [Accessed 15 November 2015].
  66. New Zealand Dermatological Society. New Zealand guidelines on the general management of malignant melanoma New Zealand. Palmerston North, NZ: NZ Dermatological Society, 2004. [Accessed 15 November 2015].
  67. Baade PD, Balanda KP, Stanton WR, Lowe JB, Del Mar CB. Community perceptions of suspicious pigmented skin lesions: Are they accurate when compared to general practitioners? Cancer Detect Prev 2005;29(3):267–75. [Accessed 15 November 2015].
  68. Kelly J, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician 2003;32(9):706–09. [Accessed 15 November 2015].
  69. Scope A, Dusza SW, Halpern AC, Rabinovitz H. The ‘ugly duckling’ sign: Agreement between observers. Arch Dermatol 2008;144(1):58–64. [Accessed 15 November 2015].
  70. Zalaudek I, Kittler H, Marghoob AA, Balato A. Time required for a complete skin examination with and without dermoscopy: A prospective, randomized multicenter study. Arch Dermatol 2008;144(4):509–13. [Accessed 15 November 2015].
  71. National Institute for Health and Care Excellence. Suspected cancer: Recognition and referral. London: NICE, 2015. [Accessed 15 November 2015].
  72. Walter FM, Prevost AT, Vasconcelos J, et al. Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: A diagnostic validation study. Br J Gen Pract 2013;63(610):e345–53. [Accessed 15 November 2015].
  73. Walter FM, Morris HC, Humphrys E, et al. Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: Randomised controlled trial. BMJ 2012;345:e4110. [Accessed 15 November 2015].
  74. Hanrahan P, D’Este CA, Menzies SW, Plummer T, Hersey P. A randomised trial of skin photography as an aid to screening skin lesions in older males. J Med Screening 2002;9(3):128–32. [Accessed 15 November 2015].
  75. English D, Del Mar C, Burton R. Factors influencing the number needed to excise: Excision rates of pigmented lesions by general practitioners. Med J Aust 2004;180(1):16–19. [Accessed 15 November 2015].
  76. Menzies SW, Emery J, Staples M, et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: A sequential intervention trial. Br J Dermatol 2009;161(6):1270–77. [Accessed 15 November 2015].
  77. Kanzler M, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: Diagnostic and therapeutic overview. J Am Acad Dermatol 2001;45(2):260–76. [Accessed 15 November 2015].
  78. Kassianos AP, Emery JD, Murchie P, Walter FM. Smartphone applications for melanoma detection by community, patient and generalist clinician users: A review. Br J Dermatol 2015;172(6):1507–18. [Accessed 15 November 2015].
  79. National Health and Medical Research Council. Clinical practice guidelines non-melanoma skin cancer: Guidelines for treatment and management in Australia. Canberra: NHMRC, 2002. [Accessed 15 November 2015].
  80. Czarnecki D, Mar A, Staples M, Giles G, Meehan C. The development of non-melanocytic skin cancers in people with a history of skin cancer. Dermatology 1994;189(4):364–67. [Accessed 15 November 2015].
  81. Australian Technical Advisory Group on Immunisation. The Australian immunisation handbook. 10th edn (2015 update). Canberra: Department of Health, 2015. [Accessed 15 November 2015].
  82. Skinner SR, Garland SM, Stanley MA, Pitts M, Quinn MA. Human papillomavirus vaccination for the prevention of cervical neoplasia: Is it appropriate to vaccinate women older than 26? Med J Aust 2008;188(4):238–42. [Accessed 15 November 2015].
  83. Cancer in Australia: an overview 2012 (online version) [Accessed 10 August 2015].
  84. Australian Government Department of Health. National Cervical Screening Program. Canberra: Department of Health, 2015 [Accessed 15 November 2015]
  85. National Health and Medical Research Council. Screening to prevent cervical cancer: Guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: NHMRC, 2005. [Accessed 15 November 2015]
  86. EUROGIN. Conclusions: Cervical cancer control, priorities and new directions: International charter. France, 2003. [Accessed 15 November 2015]
  87. Monsonego J, Bosch FX, Coursaget P, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:329–33. [Accessed 15 November 2015]
  88. Buntinx F, Brouwers M. Relation between sampling device and detection of abnormality in cervical smears: A meta-analysis of randomised and quasi-randomised studies. BMJ 1996;313(7068):1285–90. [Accessed 15 November 2015]
  89. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357(16):1579–88. [Accessed 15 November 2015]
  90. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: A systematic review and meta-analysis of nonrandomized studies. Gynecol Oncol 2007;104(1):232–46. [Accessed 15 November 2015]
  91. Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007;109(6):1325–31. [Accessed 15 November 2015]
  92. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: Triage of minor cervical lesions, follow-up of women treated for high-grade CIN: An update of pooled evidence. Gynecol Oncol 2005;99(3 Suppl 1):S7–11. [Accessed 15 November 2015]
  93. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96(4):280–93. [Accessed 15 November 2015]
  94. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: Overall results of new technologies for cervical cancer screening: Randomised controlled trial. BMJ 2007;335(7609):28. [Accessed 15 November 2015]
  95. Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: A systematic review. Lancet 2006;367(9505):122–32. [Accessed 15 November 2015]
  96. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol 2014;15(2):172–83. [Accessed 15 November 2015]
  97. Everett T, Bryant A, Griffin MF, Martin-Hirsch PPL, Forbes CA, Jepson RG. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2011;5:CD002834. [Accessed 15 November 2015]
  98. Qaseem A, Humphrey LL, Harris R, Starkey M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Screening pelvic examination in adult women: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2014;161(1):67–72. [Accessed 15 November 2015]
  99. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–303. [Accessed 15 November 2015]
  100. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2016;387(10022):945–56. [Accessed 15 November 2015]
  101. US Preventive Services Task Force. Screening for ovarian cancer: Reaffirmation recommendation statement. Am Fam Physician 2013;87(10):Online. [Accessed 15 November 2015]
  102. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184–203. [Accessed 15 November 2015]
  103. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992;80:700–07. [Accessed 15 November 2015]
  104. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805–12. [Accessed 15 November 2015]
  105. Elford RW. Screening for testicular cancer. Canadian Task Force on the Periodic Health Examination Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994; p. 892–98. [Accessed 15 November 2015]
  106. US Preventive Services Task Force. Screening for testicular cancer: Recommendation statement. Rockville, MD: Agency for Healthcare Research and Quality, 2011. [Accessed 15 November 2015]
  107. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol 2004;22(1):2–14. [Accessed 15 November 2015]
  108. National Cancer Institute. Testicular cancer screening. Bethesda, Maryland: US National Institutes of Health, 2012 screening/testicular/Patient/page3 [Accessed 15 October 2015].
  109. Cancer Council Australia Colorectal Cancer Guidelines Working Party. Cancer Guidelines Wiki: Clinical practice guidelines for the prevention, early detection and management of colorectal cancer. Sydney: Cancer Council Australia, 2017. Available at http://wiki. [Accessed 19 June 2018].
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log

Related documents

  Lifecycle charts (PDF 0.08 MB)

Advertising